Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Epidemiological Study to Evaluate Adherence to Treatment in Bipolar Disorder: Adherence Study

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00927420
First received: June 23, 2009
Last updated: October 29, 2009
Last verified: October 2009

June 23, 2009
October 29, 2009
July 2009
Not Provided
  • Morisky-Green Scale [ Time Frame: Once, at the visit moment ] [ Designated as safety issue: No ]
  • Drug Attitude Inventory Scale (DAI-10) [ Time Frame: Once, at the visit moment ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00927420 on ClinicalTrials.gov Archive Site
  • Clinical Global Impressions for Bipolar illness-modified (CGI-BP-M) [ Time Frame: Once, at the visit moment ] [ Designated as safety issue: No ]
  • Functioning Assessment Short Test (FAST) [ Time Frame: Once, at the visit moment ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Epidemiological Study to Evaluate Adherence to Treatment in Bipolar Disorder: Adherence Study
Epidemiological Study to Evaluate Adherence to Treatment in Bipolar Disorder: Adherence Study

The purpose of this study is to estimate adherence to treatment in bipolar patients, to characterize patients based on adherence degree and to describe the variables linked to poor adherence to treatment in real-life practice.

Not Provided
Observational
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Patients diagnosed with bipolar disorder I or II (DSM-IV) in ambulatory settings

Bipolar Disorder
Not Provided
1
Patients diagnosed with bipolar disorder I or II (DSM-IV) in ambulatory settings
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
300
October 2009
Not Provided

Inclusion Criteria:

  • Patients diagnosed with bipolar disorder I or II DSM-IV
  • Patients treated with at least one oral antipsychotic
  • Subjects able to read and write

Exclusion Criteria:

  • Patients participating in clinical trials
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT00927420
NIS-NES-DUM-2009/1
No
MC MD, AstraZeneca
AstraZeneca
Not Provided
Study Director: Elisa Gil AstraZeneca Spain EpidemiologyValue Demonstration Unit
AstraZeneca
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP